373 reports of this reaction
3.1% of all SEVOFLURANE reports
#4 most reported adverse reaction
BRADYCARDIA is the #4 most commonly reported adverse reaction for SEVOFLURANE, manufactured by AbbVie Inc.. There are 373 FDA adverse event reports linking SEVOFLURANE to BRADYCARDIA. This represents approximately 3.1% of all 11,848 adverse event reports for this drug.
Patients taking SEVOFLURANE who experience bradycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRADYCARDIA is moderately reported among SEVOFLURANE users, representing a notable but not dominant share of adverse events.
In addition to bradycardia, the following adverse reactions have been reported for SEVOFLURANE:
The following drugs have also been linked to bradycardia in FDA adverse event reports:
BRADYCARDIA has been reported as an adverse event in 373 FDA reports for SEVOFLURANE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRADYCARDIA accounts for approximately 3.1% of all adverse event reports for SEVOFLURANE, making it a notable side effect.
If you experience bradycardia while taking SEVOFLURANE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.